Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally approved by the US Food and Drug Administration for glycemic control in type 2 diabetes mellitus (DM2), have shown substantial cardiovascular and renal benefits, leading to their expanded use in managing heart failure (HF) and chronic...
SGLT inhibitors were designed to block the eponymous transporter in the proximal (SGLT-2) and distal (SGLT-1) tubule, which is responsible for the reabsorption of glucose filtered by the kidney glomerulus [7]. However, there is a growing body of evidence, that SGLT inhibition exerts its cardi...
The most recent therapeutic choices for the management of T2DM are dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT-2) inhibitors. In this article, we summarize the mechanism of action, the advantages and ...
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectivesKosuke Sawami, Atsushi Tanaka & Koichi Node Cardiovascular Diabetology volume 23, Article number: 410 (2024) Cite this ...
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy Article 28 September 2024 The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysi...
SGLT-2 inhibitors for COVID-19- A miracle waiting to happen or just another beat around the bush?NA+/H+ EXCHANGERThis article examines the hypothetical role of SGLT-2 inhibitors against SARS-CoV2. It also describes the pros and cons of using SGLT-2 inhibitors among COVID-19 patients....